Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
ChinaBio® Today
www.ChinaBioToday.com
ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.

News

< Previous 1 2 3 4 Next >
Fosun Closes $182 Million In-licensing of Polyphor Cancer Treatment
Fosun Pharma of Shanghai closed its $182 million in-licensing of China rights to balixafortide with Switzerland 's Polyphor AG . Balixafortide is a selective blocker of CXCR4 with multiple mechanisms,... 
Apollomics to Start China Trials of In-Licensed Leukemia Drug
Apollomics, a novel US-China oncology company, was approved to start China Phase I trial of an E-selectin inhibitor in patients with acute myeloid leukemia. China 's NMPA has also accepted a Phase III... 
Tickers GLYC
Taimei Tech Completes $176 Million Raise for AI Clinical Trial Software
aimei Technology of Shanghai completed a $176 million financing to support its AI cloud-based suite of programs for clinical trials. The company says its SAAS platform enables clinical research... 
BioShin Raises $60 Million to Bring Biohaven's Drugs to China
BioShin Limited of Shanghai raised $60 million in a Series A financing to develop Biohaven's clinical portfolio of neurological drugs in China . BioShin, a subsidiary of Biohaven, remains majority... 
Tickers SCA
Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
Junshi Biosciences of Shanghai stopped a China Phase III trial of its PD-1 checkpoint inhibitor early because it was effective in patients with nasopharyngeal carcinoma (NPC). Tuoyi (toripalimab) met... 
Junshi Says its PD-1 Effective Against Nasopharyngeal Carcinoma
Junshi Biosciences of Shanghai stopped a China Phase III trial of its PD-1 checkpoint inhibitor early because it was effective in patients with nasopharyngeal carcinoma (NPC). Tuoyi (toripalimab) met... 
Zai Lab Raises $761 Million in Hong Kong IPO; Climbs 8.5% Higher
Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion. Zai Lab has been listed on the NASDAQ exchange since 2017. An in-licensing... 
XtalPi, a US-China Ai Drug Discovery Company, Closes $319 Million C Round
XtalPi, an AI drug discovery and development company, closed a $318.8 million oversubscribed Series C funding co-led by SoftBank Vision Fund2, PICC Capital and Morningside. The company uses its... 
InventisBio Completes $147 Million Round for Small-Molecule Drugs
InventisBio, a Shanghai company developing novel small molecule drugs, completed a $147 million series D financing led by GL Ventures, a Hillhouse affiliate. It has four drug candidates in various... 
Bioray Lab Starts Tests of Gene Edited PD1-Knockin CAR-T Candidate
Bioray Laboratories of Shanghai reported positive initial results from a test of its gene-edited CAR-T therapy. The company uses gene editing to form a PD1-knockin CAR-T molecule, which it has... 
Week in Review: Illumina Pays $8 Billion to Acquire GRAIL, an Early-Stage Cancer Testing Company
Deals and Financings   Illumina will pay $8 million to acquire GRAIL, a company developing an early screening test for 50 forms of cancer based on methylation technology from Hong Kong 's Cirina; In an... 
Tickers ILMN LEGN
Sperogenix Acquires China Rights to Rare Disease Candidate in $78 Million Deal
Sperogenix Therapeutics of Beijing in-licensed a CNS drug from Barcelona 's Minoryx Therapeutics in a $78 million agreement. Sperogenix will own China rights to leriglitazone, a brain penetrating... 
BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent
BioDuro and Sundia, both of them pre-clinical China-US CROs, have partnered to form one of the largest CRDMOs with operations in China and the US . As part of the deal, Advent, a Boston  private equity... 
BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent
BioDuro and Sundia, both of them pre-clinical China-US CROs, have partnered to form one of the largest CRDMOs with operations in China and the US . As part of the deal, Advent, a Boston  private equity... 
Viva Biotech to Pay $80 Million to Acquire SYNthesis in CRO Tieup
Viva Biotech of Shanghai will pay $80 million to acquire fellow drug CRO SYNthesis Med Chem ( Hong Kong ). SYNthesis is a preclinical small molecule drug discovery CRO that specializes in high-end... 
ImmVira Raises $10 Million for Genetically Modified Oncolytic Viruses
ImmVira Group, a Shenzhen biotech, raised $10 million in a Series B to develop its next-gen genetically modified oncolytic viruses for cancer. The financing was entirely funded by Shanghai Healthcare... 
XiangXue Life Sciences to Start US Trial of Novel T-cell Receptor Candidate
XiangXue Life Sciences received US permission to start a Phase I trial of its high affinity specific T-cell receptor candidate, TCRT-ESO-A2. The molecule is China 's first TCR-T candidate to target... 
Sequoia Capital China Raising $2.2 Billion in RMB for China Fund
Sequoia Capital China is raising $2.2 billion for a new yuan-denominated fund, the company's sixth fund. The company has invested in about 600 China companies in sectors that include TMT, healthcare,... 
Genor Bio Conducting $370 Million IPO in Hong Kong
Genor Biopharma, a Shanghai company, is conducting a Hong Kong IPO that could raise up to $370 million. The company is developing a clinical-stage portfolio of 14 mAbs and recombinant fusion proteins,... 
Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina
On Monday, Illumina offered $8 billion to acquire GRAIL, an Illumina spin-out dedicated to early cancer testing. Early on, GRAIL merged with Cirina, a Hong Kong company that had developed the novel... 
Tickers ILMN
Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina
On Monday, Illumina offered $8 billion to acquire GRAIL, an Illumina spin-out dedicated to early cancer testing. Early on, GRAIL merged with Cirina, a Hong Kong company that had developed the novel... 
Tickers ILMN
JD Health Expected to Raise $3 Billion in Hong Kong IPO This Year
JD Health, a Beijing online healthcare company started by China e-commerce giant JD.com, plans to raise $3 billion in a Hong Kong IPO later this year, according to unofficial sources. In August, JD... 
Sinovac Starts Phase III Trial of COVID-19 Vaccine in Turkey
Sinovac Biotech announced the start of a Phase III trial of CoronaVac, its COVID-19 vaccine, in Turkey. The trial will first enroll 1,300 healthcare workers between the ages of 18-59, who will receive... 
Tickers SVA
Illumina to Acquire Grail, a Early Cancer Testing Company, for $8 billion
Illumina will acquire Grail, an Illumina spin-out that is developing an early screening test for multiple forms of cancer, for $8 billion in cash and stock. In 2017, Grail bought Cirina, a Hong... 
Tickers ILMN
Legend Bio's CEO Placed on House Arrest after China Investigation
Legend Biotech of Nanjing announced its CEO, Dr. Fangliang Zhang, is under China house arrest, presumably because of alleged violations of China import and export regulations. Officials from China... 
Tickers LEGN
Week in Review: Zai Lab to Raise Up To $845 Million in Hong Kong IPO
Deals and Financings   Zai Lab of Shanghai is conducting an $845 million Hong Kong IPO, a secondary listing for the company that already has a $6.2 billion capitalization on NASDAQ; Beijing-based... 
Tickers IMAB MDR MOR ZLAB
LinkDoc Raises $103 Million for Oncology AI/Big Data Services
LinkDoc Technology a Beijing oncology big data company, raised $103 million in a Series D+ funding round, primarily from new investors, CICC Capital, Youshan Capital and iFOF. Founded in 2014, LinkDoc... 
Tianjin JuveStar Enters $74 Million Deal with Raziel for Body Fat Treatment
Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel 's Raziel Therapeutics in a $74 million agreement. RZL-012 is an injectable drug... 
I-Mab and MorphoSys to Test C5aR1 Antibody in the US
Shanghai 's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors. The candidate is designed to be used... 
Tickers IMAB MOR
Zai Lab Conducting $845 Million IPO in Hong Kong
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise $845 million, based on the price of the company's US-listed shares. On the NASDAQ Exchange, Zai has a market capitalization... 
Tickers ZLAB
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.